Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).

Zhang P, Hu HR, Bian SH, Huang ZH, Chu Y, Ye DY.

Eur J Med Chem. 2013 Mar;61:95-103. doi: 10.1016/j.ejmech.2012.09.021. Epub 2012 Sep 21.

PMID:
23047001
2.

Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.

Zhang P, Hu HR, Huang ZH, Lei JY, Chu Y, Ye DY.

Bioorg Med Chem Lett. 2012 Dec 1;22(23):7232-6. doi: 10.1016/j.bmcl.2012.09.043. Epub 2012 Sep 23.

PMID:
23099099
3.

Design and synthesis of 7-hydroxy-1H-benzoimidazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.

Shin D, Lee SC, Heo YS, Lee WY, Cho YS, Kim YE, Hyun YL, Cho JM, Lee YS, Ro S.

Bioorg Med Chem Lett. 2007 Oct 15;17(20):5686-9. Epub 2007 Aug 19.

PMID:
17764934
4.

Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3β inhibitors.

La Pietra V, La Regina G, Coluccia A, Famiglini V, Pelliccia S, Plotkin B, Eldar-Finkelman H, Brancale A, Ballatore C, Crowe A, Brunden KR, Marinelli L, Novellino E, Silvestri R.

J Med Chem. 2013 Dec 27;56(24):10066-78. doi: 10.1021/jm401466v. Epub 2013 Dec 11.

PMID:
24295046
5.

Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake.

Zhang P, Li S, Gao Y, Lu W, Huang K, Ye D, Li X, Chu Y.

Bioorg Med Chem Lett. 2014 Dec 15;24(24):5639-43. doi: 10.1016/j.bmcl.2014.10.078. Epub 2014 Oct 30.

PMID:
25467150
6.

Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.

Darshit BS, Balaji B, Rani P, Ramanathan M.

J Mol Graph Model. 2014 Sep;53:31-47. doi: 10.1016/j.jmgm.2014.06.013. Epub 2014 Jul 12.

PMID:
25064440
7.

Synthesis and evaluation of 8-amino-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives as glycogen synthase kinase-3 (GSK-3) inhibitors.

Chun K, Park JS, Lee HC, Kim YH, Ye IH, Kim KJ, Ku IW, Noh MY, Cho GW, Kim H, Kim SH, Kim J.

Bioorg Med Chem Lett. 2013 Jul 1;23(13):3983-7. doi: 10.1016/j.bmcl.2013.03.119. Epub 2013 Apr 4.

PMID:
23683591
8.

Non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors: study of structural requirements for thiadiazolidinone derivatives.

Castro A, Encinas A, Gil C, Bräse S, Porcal W, Pérez C, Moreno FJ, Martínez A.

Bioorg Med Chem. 2008 Jan 1;16(1):495-510. Epub 2007 Sep 14.

PMID:
17919914
9.

A new protocol for predicting novel GSK-3β ATP competitive inhibitors.

Fang J, Huang D, Zhao W, Ge H, Luo HB, Xu J.

J Chem Inf Model. 2011 Jun 27;51(6):1431-8. doi: 10.1021/ci2001154. Epub 2011 Jun 9.

PMID:
21615159
10.

Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.

Zhao P, Li Y, Gao G, Wang S, Yan Y, Zhan X, Liu Z, Mao Z, Chen S, Wang L.

Eur J Med Chem. 2014 Oct 30;86:165-74. doi: 10.1016/j.ejmech.2014.08.049. Epub 2014 Aug 15.

PMID:
25151579
11.

Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors.

Waiker DK, Karthikeyan C, Poongavanam V, Kongsted J, Lozach O, Meijer L, Trivedi P.

Bioorg Med Chem. 2014 Mar 15;22(6):1909-15. doi: 10.1016/j.bmc.2014.01.044. Epub 2014 Jan 31.

PMID:
24530227
12.

Synthesis and biological evaluation of 3-benzisoxazolyl-4-indolylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3β.

Ye Q, Li M, Zhou Y, Pang T, Xu L, Cao J, Han L, Li Y, Wang W, Gao J, Li J.

Molecules. 2013 May 13;18(5):5498-516. doi: 10.3390/molecules18055498.

PMID:
23669633
13.

Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin.

Bidon-Chanal A, Fuertes A, Alonso D, Pérez DI, Martínez A, Luque FJ, Medina M.

Eur J Med Chem. 2013 Feb;60:479-89. doi: 10.1016/j.ejmech.2012.12.014. Epub 2012 Dec 16.

PMID:
23354070
14.

Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.

Saitoh M, Kunitomo J, Kimura E, Hayase Y, Kobayashi H, Uchiyama N, Kawamoto T, Tanaka T, Mol CD, Dougan DR, Textor GS, Snell GP, Itoh F.

Bioorg Med Chem. 2009 Mar 1;17(5):2017-29. doi: 10.1016/j.bmc.2009.01.019. Epub 2009 Jan 15.

PMID:
19200745
15.

Identification of 2-(4-pyridyl)thienopyridinones as GSK-3β inhibitors.

Gentile G, Bernasconi G, Pozzan A, Merlo G, Marzorati P, Bamborough P, Bax B, Bridges A, Brough C, Carter P, Cutler G, Neu M, Takada M.

Bioorg Med Chem Lett. 2011 Aug 15;21(16):4823-7. doi: 10.1016/j.bmcl.2011.06.050. Epub 2011 Jun 29.

PMID:
21764580
16.
17.

Famotidine inhibits glycogen synthase kinase-3β: an investigation by docking simulation and experimental validation.

Mohammad M, Al-Masri IM, Issa A, Al-Ghussein MA, Fararjeh M, Alkhatib H, Taha MO, Bustanji Y.

J Enzyme Inhib Med Chem. 2013 Aug;28(4):690-4. doi: 10.3109/14756366.2012.672413. Epub 2012 Apr 18.

PMID:
22512725
18.

Rational design of 4-amino-5,6-diaryl-furo[2,3-d]pyrimidines as potent glycogen synthase kinase-3 inhibitors.

Miyazaki Y, Maeda Y, Sato H, Nakano M, Mellor GW.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):1967-71. doi: 10.1016/j.bmcl.2008.01.113. Epub 2008 Feb 2.

PMID:
18280153
19.

Synthesis and structure-activity relationship of 4-quinolone-3-carboxylic acid based inhibitors of glycogen synthase kinase-3β.

Cociorva OM, Li B, Nomanbhoy T, Li Q, Nakamura A, Nakamura K, Nomura M, Okada K, Seto S, Yumoto K, Liyanage M, Zhang MC, Aban A, Leen B, Szardenings AK, Rosenblum JS, Kozarich JW, Kohno Y, Shreder KR.

Bioorg Med Chem Lett. 2011 Oct 1;21(19):5948-51. doi: 10.1016/j.bmcl.2011.07.073. Epub 2011 Aug 5.

PMID:
21873061
20.

Andrographolide activates the canonical Wnt signalling pathway by a mechanism that implicates the non-ATP competitive inhibition of GSK-3β: autoregulation of GSK-3β in vivo.

Tapia-Rojas C, Schüller A, Lindsay CB, Ureta RC, Mejías-Reyes C, Hancke J, Melo F, Inestrosa NC.

Biochem J. 2015 Mar 1;466(2):415-30. doi: 10.1042/BJ20140207.

PMID:
25423492

Supplemental Content

Support Center